Pilar Garcia-Broncano

Pilar Garcia-Broncano

Auto-generated profile, based on publicly available information

Pilar Garcia-Broncano

Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell
Verified
Journal Article
Closed access
NKNaoki Kaneko
Naoki Kaneko
HKHsiao-Hsuan Kuo
Hsiao-Hsuan Kuo
JBJulie Boucau
Julie Boucau
JFJocelyn R. Farmer
Jocelyn R. Farmer
HAHugues Allard-Chamard
Hugues Allard-Chamard
SPShiv Pillai
Shiv Pillai

27 November 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PGPilar Garcia-Broncano
Pilar Garcia-Broncano
SMShivaali Maddali
Shivaali Maddali
KEKevin B. Einkauf
Kevin B. Einkauf
CJChenyang Jiang
Chenyang Jiang
CGCe Gao
Ce Gao
MLMathias Lichterfeld
Mathias Lichterfeld
Antiretroviral treatment initiation immediately after birth reduces HIV-1 viral reservoir size and alters innate immune responses in neonates.

31 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DCDhan Chand
Dhan Chand
DSDavid A. Savitsky
David A. Savitsky
SKShanmugarajan Krishnan
Shanmugarajan Krishnan
GMGabriel Mednick
Gabriel Mednick
CDChloe Delepine
Chloe Delepine
RSRobert B. Stein
Robert B. Stein
Conventional immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) elicit durable survival but primarily in patients with immune-inflamed tumors. Although the mechanisms underlying response to anti–CTLA-4 remain poorly understood, Fc-gamma receptor (FcγR) IIIA coengagement seems critical for activity, potentially explaining the modest clinical benefits of approved anti–CTLA-4 antibodies. We demonstrate that anti–CTLA-4 engineered for enhanced FcγR affinity leverages FcγR-dependent mechanisms to potentiate T-cell responsiveness, reduce intratumoral regulatory T cells, and enhance antigen-presenting cell activation. Fc-enhanced anti–CTLA-4 promoted superior efficacy in mouse models and remodeled innate and adaptive immunity versus conventional anti–CTLA-4. These findings extend to patients treated with botensilimab, an Fc-enhanced anti–CTLA-4 antibody, with clinical activity across multiple poorly immunogenic and ICI treatment–refractory cancers. Efficacy was independent of tumor neoantigen burden or FCGR3A genotype. However, FCGR2A and FCGR3A expression emerged as potential response biomarkers. These data highlight the therapeutic potential of Fc-enhanced anti–CTLA-4 antibodies in cancers unresponsive to conventional ICI therapy. Significance: This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.

27 January 2016 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
CPCornelia E. Peña
Cornelia E. Peña
PGPilar García‐Broncano
Pilar García‐Broncano
MOM. Francesca Ottaviani
M. Francesca Ottaviani
MCMichela Cangiotti
Michela Cangiotti
AFAlberto Fattori
Alberto Fattori
FMFrancisco Javier De La Mata
Francisco Javier De La Mata

2 November 2018 in Cells
Verified
Journal Article
Open access
PDF file
PGPilar Garcia-Broncano
Pilar Garcia-Broncano
LMLuz Maria Medrano
Luz Maria Medrano
JBJuan Berenguer
Juan Berenguer
JGJuan Juan González-García
Juan Juan González-García
MJMaria Angeles Jimenez-Sousa
Maria Angeles Jimenez-Sousa
TGThe GESIDA 3603b Study Group
The GESIDA 3603b Study Group
Background: Advanced cirrhosis is related to alterations in immunity. We aimed to evaluate the levels of peripheral CD4+ T cells (Tregs) and plasma cytokine in patients coinfected with human immunodeficiency virus and hepatitis C virus (HIV/HCV) according to liver fibrosis stages [evaluated as liver stiffness measure (LSM)] and their linear relationship. Methods: We performed a cross-sectional study on 238 HIV/HCV-coinfected patients (119 had 25 kPa). Peripheral T-cell subsets were phenotyped by flow cytometry, plasma biomarkers were assessed by multiplex immunoassays, and LSM was assessed by transient elastography. Results: We found HIV/HCV-coinfected patients had higher values of CD4+ Tregs (p < 0.001), memory Tregs (p ≤ 0.001), and plasma cytokine levels [IFN-γ (p ≤ 0.05) and IL-10 (p ≤ 0.01)] compared with healthy donors and HIV-monoinfected patients. In the multivariate analysis, higher LSM values were associated with reduced levels of IL-10 (adjusted arithmetic mean ratio (aAMR) = 0.83; p = 0.019), IL-2 (aAMR = 0.78; p = 0.017), TNF-α (aAMR = 0.67; p < 0.001), and IL-17A (aAMR = 0.75; p = 0.006). When we focus on HIV/HCV-coinfected patients analyzed by LSM strata, patients with ≥25 kPa had lower values of IL-2 (aAMR = 0.66; p = 0.021), TNF-α (aAMR = 0.565; p = 0.003), and IL-17A (aAMR = 0.58; p = 0.003) than patients with <12.5 kPa. Conclusion: HIV/HCV-coinfected patients showed an immunosuppressive profile compared to healthy controls and HIV-monoinfected patients. Additionally, HIV/HCV-coinfected patients with advanced cirrhosis (LSM ≥ 25 kPa) had the lowest plasma values of cytokines related to Th1 (IL-2 and TNF-α) and Th17 (IL-17A) response.

1 January 2020 in Journal of Infection
Verified
Journal Article
Closed access
PGPilar Garcia-Broncano
Pilar Garcia-Broncano
LMLuz Maria Medrano
Luz Maria Medrano
JBJuan Berenguer
Juan Berenguer
ÓKÓscar Brochado Kith
Óscar Brochado Kith
JGJuan Juan González-García
Juan Juan González-García
SRSalvador Resino
Salvador Resino